Report of Foreign Issuer (6-k)

Date : 09/13/2019 @ 12:17PM
Source : Edgar (US Regulatory)
Stock : Akari Therapeutics PLC (AKTX)
Quote : 1.8301  -0.0199 (-1.08%) @ 12:59AM

Report of Foreign Issuer (6-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

September 2019

 

Commission file number: 001-36288

 

Akari Therapeutics, Plc

(Translation of registrant's name into English)

 

75/76 Wimpole Street

London W1G 9RT

United Kingdom

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x       Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

 

 

 

 

 

  

CONTENTS

 

On September 13, 2019, Akari Therapeutics, Plc (the “Company”) issued a press release announcing that the US Food and Drug Administration has granted orphan-drug designation for nomacopan for the treatment of bullous pemphigoid (BP). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

The information in this Form 6-K including the first paragraph of Exhibit 99.1 is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.

  

Exhibit No.

 

99.1 Press Release dated September 13, 2019.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Akari Therapeutics, Plc  
  (Registrant)  
       
  By: /s/ Clive Richardson  
  Name:   Clive Richardson  
    Chief Executive Officer and
Chief Operating Officer

       

Date: September 13, 2019

 

 

Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart

1 Year : From Nov 2018 to Nov 2019

Click Here for more Akari Therapeutics Charts.

Akari Therapeutics (NASDAQ:AKTX)
Intraday Stock Chart

Today : Friday 22 November 2019

Click Here for more Akari Therapeutics Charts.

Latest AKTX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.